ASC30 vs IcoSema

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07743450 (registry estimate)

No aligned efficacy figure on record for this race.

IcoSema · Kyinsu

Marketed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05352815 · Phase 3 · completed

Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.

Reported efficacy

Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)

Result source: NCT06269107

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30IcoSema
HbA1c, change—Trial running · NCT07743450-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
Body weight, change (kg)—Trial running · NCT07743450-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
HbA1c below 7%—Trial running · NCT07743450—Not posted · NCT05013229
Fasting plasma glucose, change—Trial running · NCT07743450-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
3-point MACE (% with event)—Trial running · NCT07743450—Not posted · NCT05013229

HbA1c, change

ASC30
—Trial running · NCT07743450
IcoSema
-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229

Body weight, change (kg)

ASC30
—Trial running · NCT07743450
IcoSema
-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033

HbA1c below 7%

ASC30
—Trial running · NCT07743450
IcoSema
—Not posted · NCT05013229

Fasting plasma glucose, change

ASC30
—Trial running · NCT07743450
IcoSema
-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033

3-point MACE (% with event)

ASC30
—Trial running · NCT07743450
IcoSema
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ASC30: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ASC30: 0 of 4 rows · IcoSema: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcoSema
Dropout rate
5.4%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
3.8%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Discontinued due to AEs
—
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
—
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Serious AEs
9.2%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Most frequent reported AEs
nausea 23.8%
diarrhoea 15.8%
vomiting 10.6%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
covid-19 15%
nausea 11.7%
diarrhoea 11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IcoSema

HbA1c -1.6% (n=598) vs -0.9% (n=605) Insulin Icodec @ 52wk
absolute change · percentage points
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
-1.4% (n=325) vs -0.86% (n=335) Semaglutide @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.47% vs -1.4% insulin glargine U100 + insulin aspart @ 52wk
NCT05013229 · Phase 3 · sponsor-reported, not registry data
Weight -3.71 vs 1.96 Insulin Icodec kg @ 52wk
absolute change · kg
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
0.89 vs -3.77 Semaglutide kg @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time in Range 75.9% (n=481) vs 61.9% (n=488) Insulin Icodec @ 52wk
absolute value · percentage points
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below Range 0.27 vs 0.33 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 23.2 vs 36.7 Insulin Icodec % of time @ 52wk
absolute value · % of time
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -1.9 vs -1.65 Insulin Icodec mmol/L @ 52wk
absolute change · mmol/L
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-2.74 vs -1.41 Semaglutide mmol/L @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 or 3 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 0 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · IcoSema's landscape